BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015; 7(8): 1041-1053 [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041]
URL: https://www.wjgnet.com/1007-9327/full/v7/i8/1041.htm
Number Citing Articles
1
Luigi Mele, Vitale del Vecchio, Davide Liccardo, Claudia Prisco, Melanie Schwerdtfeger, Nirmal Robinson, Vincenzo Desiderio, Virginia Tirino, Gianpaolo Papaccio, Marcella La Noce. The role of autophagy in resistance to targeted therapiesCancer Treatment Reviews 2020; 88: 102043 doi: 10.1016/j.ctrv.2020.102043
2
Chao-Nan Qian, Min-Han Tan, Jun-Ping Yang, Yun Cao. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formationChinese Journal of Cancer 2016; 35(1) doi: 10.1186/s40880-015-0070-2
3
Yongxiang Yi, Jianbo Han, Yuan Fang, Dongxiao Liu, Zuoyou Wu, Lili Wang, Liang Zhao, Qiang Wei. Sorafenib and a novel immune therapy in lung metastasis from hepatocellular carcinoma following hepatectomy: A case reportMolecular and Clinical Oncology 2016; 5(2): 337 doi: 10.3892/mco.2016.925
4
Sascha Kaufmann, Wolfgang M Thaiss, Maximilian Schulze, Michael Bitzer, Ulrich Lauer, Konstantin Nikolaou, Marius Horger. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-upActa Radiologica 2018; 59(7): 765 doi: 10.1177/0284185117732805
5
Weiwei Tang, Ziyi Chen, Wenling Zhang, Ye Cheng, Betty Zhang, Fan Wu, Qian Wang, Shouju Wang, Dawei Rong, F. P. Reiter, E. N. De Toni, Xuehao Wang. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspectsSignal Transduction and Targeted Therapy 2020; 5(1) doi: 10.1038/s41392-020-0187-x
6
Hui‐Huang Lai, Chih‐Wei Li, Chih‐Chen Hong, Hung‐Yu Sun, Ching‐Feng Chiu, Da‐Liang Ou, Pai‐Sheng Chen. TARBP 2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma Molecular Oncology 2019; 13(4): 928 doi: 10.1002/1878-0261.12449
7
Xiaomin Ma, Yumin Qiu, Lihui Zhu, Yunxue Zhao, Yueke Lin, Dapeng Ma, Zhenzhi Qin, Caiyu Sun, Xuecheng Shen, Tao Li, Lihui Han. NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinomaJournal of Molecular Medicine 2020; 98(2): 221 doi: 10.1007/s00109-019-01868-9
8
S. Colagrande, L. Calistri, C. Campani, G. Dragoni, C. Lorini, C. Nardi, A. Castellani, F. Marra. CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenibEuropean Radiology 2021; 31(3): 1608 doi: 10.1007/s00330-020-07171-3
9
Chaobo Hu, Weiping Li, Feng Tian, Kai Jiang, Xiaoting Liu, Jin Cen, Qiang He, Zhixin Qiu, Yvonne Kienast, Zhong Wang, Haibin Zhang, Yuan Ji, Junhao Hu, Lijian Hui. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinomaJournal of Hepatology 2018; 68(3): 465 doi: 10.1016/j.jhep.2017.10.028
10
K. Okrah, S. Tarighat, B. Liu, H. Koeppen, M. C. Wagle, G. Cheng, C. Sun, A. Dey, M. T. Chang, T. Sumiyoshi, Z. Mounir, C. Cummings, G. Hampton, L. Amler, J. Fridlyand, P. S. Hegde, S. J. Turley, M. R. Lackner, S. M. Huang. Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biologynpj Precision Oncology 2018; 2(1) doi: 10.1038/s41698-018-0068-8
11
Shuohui Yang, Jiang Lin, Fang Lu, Zhihong Han, Caixia Fu, Hongchen Gu. Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular CarcinomaContrast Media & Molecular Imaging 2017; 2017: 1 doi: 10.1155/2017/9265098
12
Fabio Melchiorre, Francesca Patella, Lorenzo Pescatori, Filippo Pesapane, Enrico Fumarola, Pierpaolo Biondetti, Pietro Brambillasca, Cristian Monaco, Anna Maria Ierardi, Giuseppe Franceschelli, Gianpaolo Carrafiello. DEB-TACE: a standard reviewFuture Oncology 2018; 14(28): 2969 doi: 10.2217/fon-2018-0136
13
Kwon Yong Tak, Hee Chul Nam, Jong Young Choi, Seung Kew Yoon, Chang Wook Kim, Hee Yeon Kim, Sung Won Lee, Hae Lim Lee, U Im Chang, Do Seon Song, Jin Mo Yang, Jung Hyun Kwon, Sun Hong Yoo, Pil Soo Sung, Sang Wook Choi, Myeong Jun Song, Seok Hwan Kim, Jeong Won Jang. Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: Analysis in real‐life settingsInternational Journal of Cancer 2020; 147(7): 1970 doi: 10.1002/ijc.32964
14
Shuo-hui Yang, Jiang Lin, Fang Lu, Zhi-hong Han, Cai-xia Fu, Peng Lv, Hao Liu, Dong-mei Gao. Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft modelJournal of Magnetic Resonance Imaging 2017; 45(1): 270 doi: 10.1002/jmri.25344
15
Chunye Zhang, Ming Yang, Aaron C. Ericsson. The Potential Gut Microbiota-Mediated Treatment Options for Liver CancerFrontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.524205
16
Roberto Mazzanti, Umberto Arena, Renato Tassi. Hepatocellular carcinoma: Where are we?World Journal of Experimental Medicine 2016; 6(1): 21-36 doi: 10.5493/wjem.v6.i1.21
17
Daniela Coelho Santos, Jamal Rafique, Sumbal Saba, Gabriela M. Almeida, Tâmila Siminski, Cynthia Pádua, Danilo W. Filho, Ariane Zamoner, Antonio L. Braga, Rozangela C. Pedrosa, Fabiana Ourique. Apoptosis oxidative damage‐mediated and antiproliferative effect of selenylated imidazo[1,2‐ a ]pyridines on hepatocellular carcinoma HepG2 cells and in vivo Journal of Biochemical and Molecular Toxicology 2021; 35(3) doi: 10.1002/jbt.22663
18
Cassia Regina Guedes Leal, Cristiane Magalhães, Daniel Barbosa, Diogo Aquino, Bernardo Carvalho, Elizabeth Balbi, Lucio Pacheco, Renata Perez, Paulo de Tarso Pinto, Sérgio Setubal. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective studyInvestigational New Drugs 2018; 36(5): 911 doi: 10.1007/s10637-018-0621-x
19
Stefan F. Thieme, Janis L. Vahldiek, Katja Tummler, Franz Poch, Ole Gemeinhardt, Bernhard Hiebl, Kai S. Lehmann, B. Hamm, Stefan M. Niehues, L. Prantl, E.M. Jung, F. Jung. Value or waste: Perfusion imaging following radiofrequency ablation – early experienceClinical Hemorheology and Microcirculation 2015; 61(2): 323 doi: 10.3233/CH-152000
20
Zoe Leung, Frankie Chi Fat Ko, Sze Keong Tey, Ernest Man Lok Kwong, Xiaowen Mao, Bonnie Hei Man Liu, Angel Po Yee Ma, Yi Man Eva Fung, Chi-Ming Che, Danny Ka Ho Wong, Ching Lung Lai, Irene Oi-Lin Ng, Judy Wai Ping Yam. Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cellsJournal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1402-x
21
Marta Campos, Isabel Candelária, Nickolas Papanikolaou, Adélia Simão, Carlos Ferreira, Georgios C. Manikis, Filipe Caseiro-Alves. Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot StudyGE - Portuguese Journal of Gastroenterology 2019; 26(4): 260 doi: 10.1159/000493351
22
Guoqing Ouyang, Guangdong Pan, Honglai Xu, Yongrong Wu, Zhen Liu, Wuhang Lu, Bin Yi, Xiang Chen. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular CarcinomaJournal of Clinical Gastroenterology 2020; 54(8): 675 doi: 10.1097/MCG.0000000000001384